Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
Launched by VANDA PHARMACEUTICALS · Apr 13, 2021
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to provide written consent
- • Body Mass Index (BMI) of 18-35 kg/m2
- • No medical problems or chronic diseases
- Exclusion Criteria:
- • Diagnosis of gastrointestinal diseases
- • Structural or metabolic diseases that affect the GI system
- • A positive test for drugs of abuse at screening
About Vanda Pharmaceuticals
Vanda Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with unmet medical needs, particularly in the fields of psychiatry and sleep disorders. With a strong focus on precision medicine, Vanda leverages cutting-edge research and clinical trial methodologies to advance novel treatments that improve patient outcomes. The company's commitment to scientific excellence and patient-centric approaches positions it as a leader in delivering transformative healthcare solutions. Through its robust pipeline and strategic partnerships, Vanda aims to enhance the quality of life for individuals affected by complex medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Vanda Pharmaceuticals
Study Director
Vanda Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials